%0 Journal Article
%T Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study
%A Agnieszka Julia Slowik
%A Andrzej Budzy¨½ski
%A Kamil Fijorek
%A Kamil Konopka
%A Micha£¿ P£¿dziwiatr
%A Miros£¿awa Puskulluoglu
%A Sebastian Ochenduszko
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2017
%R 10.1177/1758834016689029
%X Randomized clinical trials showed improved overall survival (OS) of advanced gastroesophageal adenocarcinoma (GEA) patients treated with second-line taxane or irinotecan. However, most data on irinotecan efficacy in this setting come from large Asian trials. We retrospectively analyzed clinical effectiveness and toxicity of irinotecan in a cohort of patients with advanced GEA treated in our department
%K gastric cancer
%K gastroesophageal cancer
%K irinotecan
%K second-line chemotherapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405997/